The mucinous-like carcinoma-associated antigen (MCA), a new tumour marker, was dosed in 150 serous effusions. The levels of MCA were measured by means of an enzyme immunoassay (EIA). Ninety-seven were pleural effusions, 49 were peritoneal effusions and 4 were pericardial effusions. Thirty-five effusions were caused by breast carcinoma, 19 by ovarian carcinoma, 17 by pulmonary carcinoma, 19 by various cancers, while 60 effusions turned out to be of non-neoplastic origin. The results were considered in comparison with the cytologic examination, and the data obtained were also elaborated in terms of sensitivity, specificity, predictive value and test efficiency. The EIA showed satisfactory statistical parameters principally regarding ovarian metastatic cancer. On the other hand, less satisfactory results were extrapolated on breast and lung cancers. Even if further studies are necessary, for example to compare MCA with other seric tumour markers, this experience suggests that MCA could be a satisfactory tumour marker in the diagnosis of metastatic ovarian effusions.

Keywords:
Tumour marker, Serous effusion, Enzyme immunoassay
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.